Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PHARMATROPHIX, INC. via FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
2026 · third_quarter · Q3
Lobbying related to clinical trial funding.
Lobbying related to clinical trial funding.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
2026 · third_quarter · Q3
Lobbying related to securing funding from the CARES and Paycheck Protection and Health Care Enhancement Acts as well as future economic stimulus legislation and tele-physical therapy.
Lobbying related to securing funding from the CARES and Paycheck Protection and Health Care Enhancement Acts as well as future economic stimulus legislation and tele-physical therapy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMATROPHIX, INC. via FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
2026 · second_quarter · Q2
Lobbying related to clinical trial funding.
Lobbying related to clinical trial funding.
Filing targets: Executive Office of the President (EOP), SENATE
HOSPITAL FOR SPECIAL SURGERY via FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
2026 · second_quarter · Q2
Lobbying related to securing funding from the CARES and Paycheck Protection and Health Care Enhancement Acts as well as future economic stimulus legislation and tele-physical therapy.
Lobbying related to securing funding from the CARES and Paycheck Protection and Health Care Enhancement Acts as well as future economic stimulus legislation and tele-physical therapy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHARMATROPHIX, INC. via FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
2026 · second_quarter · RR
Lobbying related to clinical trial funding.
Lobbying related to clinical trial funding.
HOSPITAL FOR SPECIAL SURGERY via FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
2026 · first_quarter · Q1
Lobbying related to securing funding from the CARES and Paycheck Protection and Health Care Enhancement Acts as well as future economic stimulus legislation and tele-physical therapy.
Lobbying related to securing funding from the CARES and Paycheck Protection and Health Care Enhancement Acts as well as future economic stimulus legislation and tele-physical therapy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HOSPITAL FOR SPECIAL SURGERY via FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
2025 · fourth_quarter · Q4
Lobbying related to securing funding from the CARES and Paycheck Protection and Health Care Enhancement Acts as well as future economic stimulus legislation and tele-physical therapy.
Lobbying related to securing funding from the CARES and Paycheck Protection and Health Care Enhancement Acts as well as future economic stimulus legislation and tele-physical therapy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HOSPITAL FOR SPECIAL SURGERY via FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
2025 · third_quarter · Q3
Lobbying related to developing a national solution to preserve the unique model of American athletics, while modernizing the system to increase economic opportunity for all student-athletes on issues surrounding their name, image, and likeness.
Lobbying related to developing a national solution to preserve the unique model of American athletics, while modernizing the system to increase economic opportunity for all student-athletes on issues surrounding their name, image, and likeness.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HOSPITAL FOR SPECIAL SURGERY via FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
2025 · second_quarter · Q2
Lobbying related to developing a national solution to preserve the unique model of American athletics, while modernizing the system to increase economic opportunity for all student-athletes on issues surrounding their name, image, and likeness.
Lobbying related to developing a national solution to preserve the unique model of American athletics, while modernizing the system to increase economic opportunity for all student-athletes on issues surrounding their name, image, and likeness.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SCIPHER MEDICINE CORPORATION via FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
2024 · first_quarter · 1T
Lobbying related to CMS coverage determination.
Lobbying related to CMS coverage determination.
SCIPHER MEDICINE CORPORATION via FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
2023 · fourth_quarter · Q4
Lobbying related to CMS coverage determination.
Lobbying related to CMS coverage determination.
SCIPHER MEDICINE CORPORATION via FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
2023 · third_quarter · Q3
Lobbying related to CMS coverage determination.
Lobbying related to CMS coverage determination.
Filing targets: Health & Human Services, Dept of (HHS)
SCIPHER MEDICINE CORPORATION via FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
2023 · second_quarter · Q2
Lobbying related to CMS coverage determination.
Lobbying related to CMS coverage determination.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SCIPHER MEDICINE CORPORATION via FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
2023 · first_quarter · Q1
Lobbying related to CMS coverage determination.
Lobbying related to CMS coverage determination.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
SCIPHER MEDICINE CORPORATION via FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC)
2023 · first_quarter · RR
Lobbying related to CMS coverage determination
Lobbying related to CMS coverage determination